n
a
v
Portfolio
Genetics
AmplideX® mPCR FMR1 Kit
AmplideX® PCR/CE FMR1 Kit
AmplideX® FMR1 Controls
Xpansion Interpreter®
AmplideX® PCR/CE
SMN1/2
Plus Kit
AmplideX® PCR/CE
CFTR
Kit
AmplideX® PCR/CE C9orf72 Kit
AmplideX® PCR/CE
DMPK
Kit
AmplideX® PCR/CE
HTT
Kit
AmplideX® TRIO
Oncology
QuantideX® qPCR BCR-ABL IS Kit
QuantideX® qPCR BCR-ABL minor Kit
QuantideX® qPCR
ESR1
exoMutation Kit [Coming Soon]
QuantideX® qPCR PML-RARA Kit* [Coming Soon]
MolecularDx Controls
Catalog of Armored Products
SARS CoV-2 Controls
Made-To-Order Armored and Nucleic Acid
Molecular Assay Reagents
Custom & Companion Diagnostics
Partnered R&D
CAP-Accredited CLIA Lab
CTA Testing Site
Validated Platforms & Assays
Companion Diagnostics
Enabling Technologies
Assay Chemistries
Bioinformatics
Product Development Process
Resources
Publications
Articles
Whitepapers
Posters
Disease Information
Fragile X Syndrome
Dementia
Chronic Myeloid Leukemia (CML)
Other Resources
Videos
Carrier Screening Guide
Safety Data Sheets
Sales Contacts
Our Culture
Employee Spotlights
Culture & Heritage
Sales Contacts
Contact
EMEA
About
Leadership Team
Culture and Heritage
News
Upcoming Events
Business Development
Careers
Search
News
Home
News
Press Releases
Year
Select Year
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
November 8, 2016
Asuragen to Present at 2016 Association for Molecular Pathology Annual Meeting
Share
August 9, 2016
Asuragen Develops Armored RNA Quant® Zika Virus Control
Share
July 25, 2016
Asuragen’s QuantideX® qPCR BCR-ABL IS Kit Receives FDA Premarket Clearance for Monitoring Minimal Residual Disease in Chronic Myeloid Leukemia
Share
July 6, 2016
Asuragen Launches the AmplideX® PCR/CE C9orf72 Kit for High-Resolution Genotyping of GC-rich Repeat Expansions Relevant to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Share
December 5, 2015
Asuragen Launches AmplideX® PCR/CE FMR1 Reporter*, a Fully Automated Software Solution for Accurate Sizing of the FMR1 CGG Repeat Region
Share
September 9, 2015
Asuragen to Collaborate with Illumina on Companion Diagnostics Development
Share
January 12, 2015
Asuragen to join leading UK cancer research consortium to develop miRNA based sequencing tests for early detection and screening of cancer
Share
September 17, 2014
Asuragen’s Xpansion Interpreter® Test Study of 1,040 Transmissions of Fragile X Alleles Reveals Personalized Risks for Expansion from Parent to Child
Share
September 4, 2014
Asuragen and Labceutics Report Results from Pan European Quality Assurance-Modeled Study on Standardization of BCR-ABL1 Monitoring for CML Patients
Share
April 23, 2013
Asuragen announces publication on standardization of BCR-ABL1 testing on the international scale
Share
Prev
1
2
3
4
5
6
Next
About
About
Leadership Team
Culture and Heritage
News
Upcoming Events
Business Development
Back To
Top